Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
NN-6491 by Novo Nordisk for Dyslipidemia: Likelihood of Approval
NN-6491 is under clinical development by Novo Nordisk and currently in Phase I for Dyslipidemia. According to GlobalData, Phase I...